71 results about "Neo angiogenesis" patented technology

The present invention relates to a heparin-derivatized collagen matrix comprising a fragment of heparin covalently linked to a collagen scaffold, wherein the fragment of heparin has molecular weight of less than about 15 kDa, and at least one heparin-binding growth factor (HBGF) or heparin-binding adeno-associated virus (HB-AAV) or a combination thereof and methods for promoting bone growth, bone repair, cartilage repair, bone development, neo-angiogensis, wound healing, tissue engraftment and muscle tissue regeneration and / or tissue augmentation comprising administering a heparin-derivatized collagen matrix that includes at least one heparin-binding growth factor or heparin-binding adeno-associated virus or a combination thereof.

The present invention relates to ophthalmic pharmaceutical compositions comprising Sorafenib, its derivatives or active metabolites, for the treatment and prevention of ocular neoangiogenic pathologies.

The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLT1, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDR1 and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.

The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent. The method treats ongoing vascular insufficiency affecting coronary circulation by (i) stimulating neoangiogenesis in a peri-infarct border zone, thereby improving myocardial perfusion; and, (ii) through a paracrine effect, preventing apoptosis of cardiomyocytes in the peri-infarct border zone. The neoangiogenesis and paracrine-mediated reduction of apoptosis reduces progressive myocardial cell loss, which leads to improvement in cardiac function and a reduction of risk of major adverse cardiovascular events.

The present invention describes novel compounds of the formula:(Q)d—Ln—Ch,useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

The invention discloses application of scutellarein in preparing angiogenesis treatment medicines, and belongs to the field of pharmacy. Experimental study proves that the scutellarein has higher angiogenesis inhibition function, and has exact prevention and treatment functions on angiogenesis-related diseases such as tumor, leukemia, lymphoma and hemangioma angiogenesis, benign angiogenesis, arthritis diseased tissue angiogenesis, eye diseased tissue angiogenesis and the like, and meanwhile, the scutellarein also has remarkable inhibition on stigmatization during wound healing. The scutellarein can directly act on endothelial cells of vessels, has small administration dosage and high clinical effect during clinical application, side effects are small, and drug resistance is not generated easily.

The invention provides application of polysaccharide sulphate to preparation of tumor treatment neovascularization inhibitors and vascular disrupting agents. Experiments prove that the neovascularization inhibiting rate, the maturation blood vessel disrupting rate and the concentration of the polysaccharide sulphate are in dosage relying relationship in a certain range, and the maturation blood vessel disrupting rate and the polysaccharide sulphate acting time are in dosage relying relationship. The application provided by the invention has the advantages that the effect of the polysaccharide sulphate in the aspects of tumor neovascularization inhibiting and tumor blood vessel generation disrupting can be proved, and the polysaccharide sulphate can be used for tumor blood vessel generation and other blood vessel generation disease treatment, and can also be used in aspects of tumor chemotherapy and / or auxiliary chemotherapy. Many diseases of people are relevant to the blood vessel generation, and the polysaccharide sulphate as the neovascularization inhibitors and vascular disrupting agents can be widely applied to the treatment of diseases of tumor and the like. The application provided by the invention has the advantages that the application range of the polysaccharide sulphate is widened, and the scientific basis is provided for the purpose development of the polysaccharide sulphate in the anti-tumor aspect and the like.

The present invention describes novel compounds of the formula:(Q)d-Ln-Ch,useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

The invention relates to a peptide for high performance inhibition of angiogenesis and method for preparing same and use, wherein high performance blood vessel production inhibiting agent RGD-ED with integration compatibility is designed, the inhibiting agent comprises polypeptide polypeptide-valine-arginine-arginine-alanine-aspartate-arginine-alanine-alanine-valine-praline, its one or two ends are connected with polypeptides containing arginine-glycine-aspartic acid sequence. The RGD-ED provided by the invention can be synthesized. The invention also discloses the expression of one RGD-ED in bacillus coli through gene engineering method, wherein the RGD-ED is prepared through the steps of inclusion body protein segregation, dissolution and renaturation, and ion-exchange chromatography segregation and purification.

The present invention refers to pharmaceutical preparations including as active compounds 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I) and / or their dimers of general formula (II) and (III) acting as agonists of human neurotrophines. Therefore, such compounds of formula (I), (II) and (III) are useful for treatment of diseases in which the neurotrophine functions are involved in defect, particularly of Nerve Growth Factor (NGF), such as neurodegenerative diseases of central nervous system (CNS), acquired immunodeficiency due to a reduced NGF biodisponibility, or morbous conditions in which the stimulus of neoangiogenesis process is convenient.

The invention discloses application of codonopsis pilosula polysaccharides to the preparation of a functional food with the effect of helping to inhibit prostate cancer. Optimally, the codonopsis pilosula polysaccharides are prepared from codonopsis pilosula and by the procedures of extracting with boiled water, removing proteins, carrying out dialysis and carrying out ethanol treatment. The codonopsis pilosula polysaccharides have the effect of adjusting a tumor microenvironment through a plurality of manners of inhibiting tumor angiogenesis, carrying out immune activation, inhibiting fibroblast growth of prostate cancer and the like, so that the codonopsis pilosula polysaccharides have the good effect of helping to inhibit prostate cancer.

A pharmaceutical composition and a method of treating ischemic heart diseases by growing new blood vessels that supply oxygen and nutrients to infarcted heart tissues throughout the entire infarct zone and for preventing cardiomyocyte apoptosis in ischemic events. The pharmaceutical composition contains an active ingredient compound with a backbone structure of formula (I).

The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.

The invention relates to a chicken germ yolk capsular vessel generating model, as living test model for detecting or selecting the drug which can affect novel vessel. The invention comprises that removing frame of 60h old germ to be put into a small beaker to cultivate for 12h, adding object drug into a silica gel ring on the yolk capsule, the contrast liquid and object liquid both contain glycerin or dimethyl sulfoxide as penetrant, taking off the silica gel ring after 12h, dynamically watching the effect of drug on the yolk capsular vessel. The function of drug on the vessel as restrain, simulate or non function can be judged according to the growth state of the yolk capsular vessel. Compared with traditional model, the invention is simple, visual, quick and accurate.

The invention relates to a cRGD-quaternized chitosan oligosaccharide modified ES2 peptide-methotrexate conjugate as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The CREM peptide conjugate can be prepared by controlling the conditions such as the supply quantity of the cRGD, the ES2 peptide and the MTX, the pH of a reaction system, the reaction time and the like. Compared with the ES2 peptide, the cRGD-quaternized chitosan oligosaccharide modified and methotrexate combined conjugate of the ES2 peptide keeps the anti-angiogenesis and anti-tumor activity of the ES2 peptide, integrates the tumor targeting property of cRGD and the anti-tumor activity of methotrexate and the like, has the characteristics of higher stability, hydrophilicity, targeting property and the like; therefore, the oligosaccharide has better use effect and application value.